Lattice Distortion of Crystalline-amorphous nickel molybdenum sulfide nanosheets for high-efficiency overall water splitting: lone pair electrons’ libraries and in-suit surface reconstitution

Lattice distortion is an important way to improve the electrocatalytic performance and stability of two-dimensional transition metal materials (2d-TMSs). Herein, a lattice distortion nickel-molybdenum sulfide electrocatalyst on foam nickel (NiMoS4-12/NF)...

The First Interchangeable Biosimilar Insulin: Insulin Glargine-yfgn

On March 23, 2020, all insulin products were reclassified as biologics instead of drugs under the Biological Price Competition and Innovation (BPCI) Act of 2009. This allows biosimilar insulin products to be manufactured when the patent expires for the reference biologic, sometimes called the originator or brand name product. A biosimilar product may not be substituted for the reference biologic at the pharmacy counter unless the biosimilar undergoes further switch trials to earn the designation as an interchangeable biosimilar. Insulin glargine-yfgn 100 units/mL is the first biosimilar insulin to attain interchangeable status with the reference insulin glargine. In the INSTRIDE 1 and INSTRIDE 2 trials, insulin glargine-yfgn has proven noninferiority regarding blood glucose reduction and adverse effect profile versus reference insulin glargine; even in the INSTRIDE 3 trial in which treatment of diabetes was switched between insulin glargine-yfgn and reference insulin glargine throughout the trial without statistically significant changes to glucose levels or adverse effects. Insulin glargine-yfgn may be substituted at the pharmacy counter without consultation with the prescriber, in accordance with state laws. In suit with other biosimilars, insulin glargine-yfgn’s list price is significantly lower than other insulin glargine products. This increases market competition leading to decreases in costs of other insulin glargine products. Many patients who could not previously afford insulin therapy may now have significantly improved access to treatment. Providers will need education to increase awareness of these new biosimilars and interchangeable biosimilar insulin products, cost benefits, and substitution allowances.

A Glider Simulation Model Based on Optimized Support Vector Regression for Efficient Coordinated Observation

Multi-gliders have been widely deployed as an array in nowadays ocean observation for fine and long-term ocean research, especially in deep-sea exploration. However, the strong, variable ocean currents and the delayed information feedback of gliders are remaining huge challenges for the deployment of glider arrays which may cause that the observed data cannot meet the study needs and bring a prohibitive cost. In this paper, we develop a Glider Simulation Model (GSM) based on the support vector regression with the particle swarm optimization (PSO)-SVR algorithm to integrate the information feedback from gliders and ocean current data for rapid modeling to effectively predict the gliders’ trajectories. Based on the real-time predictive information of the trajectories, each glider can select future movement strategies. We utilize the in-suit datasets obtained by sea-wing gliders in ocean observation to train and test the simulation model. The results show that GSM has an effective and stable performance. The information obtained from the modeling approaches can be utilized for the optimization of the deployment of the glider arrays.

A Novel 2D Graphene Oxide Modified α-AgVO3 Nanorods: Design, Fabrication and Enhanced Visible-Light Photocatalytic Performance

Silver vanadates are promising visible-light-responded photocatalysts with suitable bandgap for solar absorption. However, the easy recombination of photogenerated carriers limits their performance. To overcome this obstacle, a novel 2D graphene oxide (GO) modified α-AgVO3 nanorods (GO/α-AgVO3) photocatalyst was designed herein to improve the separation of photocarriers. The GO/α-AgVO3 was fabricated through a facile in-suit coprecipitation method at room temperature. It was found that the as-prepared 0.5 wt.% GO/α-AgVO3 exhibited the most excellent performance for Rhodamine B (RhB) decomposition, with an apparent reaction rate constant 18 times higher than that of pure α-AgVO3 under visible-light irradiation. In light of the first-principles calculations and the heterojunction analysis, the mechanism underpinned the enhanced photocatalytic performance was proposed. The enhanced photocatalytic performance was ascribed to the appropriate bandgap of α-AgVO3 nanorods for visible light response and efficient separation of photocarriers through GO nanosheets. This work demonstrates the feasibility of overcoming the easy recombination of photogenerated carriers and provides a valuable GO/α-AgVO3 photocatalyst for pollutant degradation.

Eicosapentaenoic Acid Inhibits KRAS Mutant PancreaticCancer Cell Growth by Suppressing Hepassocin Expression and STAT3 Phosphorylation

Background: The oncogenic Kirsten rat sarcoma viral oncogene homolog (KRAS) mutation was reported to be the signature genetic event in most cases of pancreatic ductal adenocarcinoma (PDAC). Hepassocin (HPS/FGL1) is involved in regulating lipid metabolism and the progression of several cancer types; however, the underlying mechanism of HPS/FGL1 in the KRAS mutant PDAC cells undergoing eicosapentaenoic acid (EPA) treatment remains unclear. Methods: We measured HPS/FGL1 protein expressions in a human pancreatic ductal epithelial (HPNE) normal pancreas cell line, a KRAS-wild-type PDAC cell line (BxPC-3), and KRAS-mutant PDAC cell lines (PANC-1, MIA PaCa-2, and SUIT-2) by Western blot methods. HEK293T cells were transiently transfected with corresponding KRAS-expressing plasmids to examine the level of HPS expression with KRAS activation. We knocked-down HPS/FGL1 using lentiviral vectors in SUIT-2 cells and measured the cell viability by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) and clonogenicity assays. Furthermore, a lipidomic analysis was performed to profile changes in lipid metabolism after HPS/FGL1 knockdown. Results: We found that the HPS/FGL1 level was significantly upregulated in KRAS-mutated PDAC cells and was involved in KRAS/phosphorylated (p)-signal transduction and activator of transcription 3 (STAT3) signaling, and the knockdown of HPS/FGL1 in SUIT-2 cells decreased cell proliferation through increasing G2/M cell cycle arrest and cyclin B1 expression. In addition, the knockdown of HPS/FGL1 in SUIT-2 cells significantly increased omega-3 polyunsaturated fatty acids (PUFAs) and EPA production but not docosahexaenoic acid (DHA). Moreover, EPA treatment in SUIT-2 cells reduced the expression of de novo lipogenic protein, acetyl coenzyme A carboxylase (ACC)-1, and decreased p-STAT3 and HPS/FGL1 expressions, resulting in the suppression of cell viability. Conclusions: Results of this study indicate that HPS is highly expressed by KRAS-mutated PDAC cells, and HPS/FGL1 plays a crucial role in altering lipid metabolism and increasing cell growth in pancreatic cancer. EPA supplements could potentially inhibit or reduce ACC-1-involved lipogenesis and HPS/FGL1-mediated cell survival in KRAS-mutated pancreatic cancer cells.